
Xarelto gains EU approval
The European Commission has granted marketing approval to the Bayer Group for Xarelto (rivaroxaban), an anticoagulant taken as one tablet, once-daily, to prevent venous thrombo-embolic events (VTE) in adults undergoing elective (planned) hip or knee replacement surgery.






















